Edwards Lifesciences Co. (NYSE:EW) Shares Bought by LMR Partners LLP

LMR Partners LLP increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,643 shares of the medical research company's stock after purchasing an additional 26,443 shares during the period. LMR Partners LLP's holdings in Edwards Lifesciences were worth $9,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth $26,000. Millstone Evans Group LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $30,000. Roble Belko & Company Inc purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $46,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Evercore ISI reduced their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $79.60.

Insider Activity at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,150,791.86. The trade was a 27.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,931 shares of company stock worth $5,148,028. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.1%

EW stock traded up $0.04 during mid-day trading on Thursday, hitting $76.79. 4,508,636 shares of the company were exchanged, compared to its average volume of 5,078,558. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The firm has a market capitalization of $45.05 billion, a P/E ratio of 11.02, a PEG ratio of 4.82 and a beta of 1.12. The business has a fifty day simple moving average of $71.73 and a 200-day simple moving average of $71.62. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.66 EPS. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.